Accordingly, pharmacological inhibition of HMG-CoA reductase— the rate-limiting enzyme of the mevalonate pathway—using simvastatin could fully rescue CAR T-cell-mediated killing of TP53-mutant AML cells. Here, TP53 is linked to acute myeloid leukemia.